



Title	Relationship between laparoscopic total gastrectomy-associated postoperative complications and gastric cancer prognosis
Author(s)	Ebihara, Yuma; Kyogoku, Noriaki; Murakami, Yoshihiro; Murakawa, Katsuhiko; Nakamura, Fumitaka; Morita, Takayuki; Okushiba, Shunichi; Hirano, Satoshi
Citation	Updates in surgery, 75(1), 149-158 <a href="https://doi.org/10.1007/s13304-022-01402-6">https://doi.org/10.1007/s13304-022-01402-6</a>
Issue Date	2023-01-01
Doc URL	<a href="http://hdl.handle.net/2115/91066">http://hdl.handle.net/2115/91066</a>
Rights	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature 's AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: <a href="http://dx.doi.org/10.1007/s13304-022-01402-6">http://dx.doi.org/10.1007/s13304-022-01402-6</a>
Type	article (author version)
File Information	Updates Surg 75 149-158.pdf



[Instructions for use](#)

1 **Title page**

2 **Original Article**

3 **Title:** Relationship between laparoscopic total gastrectomy-associated postoperative complications and gastric  
4 cancer prognosis

5 **Authors:**

6 Yuma Ebihara, PhD<sup>1,2</sup>, Noriaki Kyogoku, PhD<sup>3</sup>, Yoshihiro Murakami, PhD<sup>4</sup>, Katsuhiko Murakawa, PhD<sup>5</sup>,  
7 Fumitaka Nakamura, PhD<sup>6</sup>, Takayuki Morita, PhD<sup>7</sup>, Shunichi Okushiba, PhD<sup>8</sup>, Satoshi Hirano, PhD<sup>1</sup>

8

9 **Affiliations:**

10 <sup>1</sup>Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan;

11 <sup>2</sup>Division of Minimally Invasive Surgery, Hokkaido University Hospital, Sapporo, Japan;

12 <sup>3</sup>Department of Surgery, Kitami Red Cross Hospital, Kitami, Japan;

13 <sup>4</sup>Department of Surgery, Asahikawa City Hospital, Asahikawa, Japan;

14 <sup>5</sup>Department of Surgery, ObihiroKosei General Hospital, Obihiro, Japan;

15 <sup>6</sup>Department of Surgery, Teine Keijinkai Hospital, Sapporo, Japan;

16 <sup>7</sup>Department of Surgery, Hokkaido Gastroenterology Hospital, Sapporo, Japan;

17 <sup>8</sup>Department of Surgery, Tonan Hospital, Sapporo, Japan

18

19 **Corresponding author:**

20 Yuma Ebihara, Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Kita 15  
21 Nishi 7, Kita-ku, Sapporo City, 060-8638, Japan

22 Tel: +81 11 706 7714 Fax: +81 11 706 7158

23 Email: yuma-ebi@wc4.so-net.ne.jp

24

25

26 **Acknowledgments:**

27 The author is grateful to our colleagues (Drs. Hiroshi Kawase and Mamoru Miyasaka) and the interdisciplinary  
28 surgical team. We would like to thank Editage (www.editage.com) for English language editing.

29

30 **Declarations:**

1 **Conflict of Interest:**

2 The authors have no conflicts of interest to declare.

3

4 **Funding:**

5 No funding support was received for this study.

6

7 **Ethics approval:**

8 Hokkaido University Hospital Institutional Review Board approved the data collection and analysis (No. 016-  
9 0151).

10

11 **Consent to participate:**

12 All study participants provided informed consent, and the study design was approved by the appropriate ethics  
13 review board.

14

15 **Consent to publish:**

16 Not applicable.

17

18 **Data availability statement:**

19 The datasets generated and analyzed during the current study are available from the corresponding author on  
20 reasonable request

21

22 **Author Contributions:**

23 Study conception and design: Yuma Ebihara and Satoshi Hirano.

24 Acquisition of data: Yuma Ebihara.

25 Analysis and interpretation of data: Yuma Ebihara and Satoshi Hirano.

26 Drafting of manuscript: Yuma Ebihara.

27 Critical revision of the manuscript: Yuma Ebihara, Noriaki Kyogoku, Yoshihiro Murakami, Katsuhiko Murakawa,

28 Fumitaka Nakamura, Takayuki Morita, Shunichi Okushiba, and Satoshi Hirano.

29

30

1        **Original Article**

2        Title: Relationship between laparoscopic total gastrectomy-associated postoperative complications and  
3 gastric cancer prognosis

4  
5        **Abstract**

6        This study aimed to investigate the incidence and prognosis of postoperative complications after  
7 laparoscopic total gastrectomy (LTG) for gastric cancer (GC). We retrospectively enrolled 411 patients who  
8 underwent curative LTG for GC at seven institutions between January 2004 and December 2018. The  
9 patients were divided into two groups, complication group (CG) and non-complication group (non-CG),  
10 depending on the presence of serious postoperative complications (Clavien-Dindo grade III [ $\geq$ CD IIIa] or  
11 higher complications). Short-term outcomes and prognoses were compared between two groups. Serious  
12 postoperative complications occurred in 65 (15.8%) patients. No significant difference was observed  
13 between the two groups in the median operative time, intraoperative blood loss, number of lymph nodes  
14 harvested, or pathological stage; however, the 5-year overall survival (OS; CG 66.4% vs. non-CG 76.8%;  $p$   
15 = 0.001), disease-specific survival (DSS; CG 70.1% vs. non-CG 76.2%;  $p$  = 0.011), and disease-free survival  
16 (CG 70.9% vs. non-CG 80.9%;  $p$  = 0.001) were significantly different. The Cox multivariate analysis  
17 identified the serious postoperative complications as independent risk factors for 5-year OS (HR 2.143, 95%  
18 CI 1.165–3.944,  $p$  = 0.014) and DSS (HR 2.467, 95% CI 1.223–4.975,  $p$  = 0.011). A significant difference  
19 was detected in the median days until postoperative recurrence (CG 223 days vs. non-CG 469 days;  $p$  =  
20 0.017) between the two groups. Serious postoperative complications after LTG negatively affected the GC  
21 prognosis. Efforts to decrease incidences of serious complications should be made that may help in better  
22 prognosis in patients with GC after LTG.

23  
24        Keywords: laparoscopic total gastrectomy, gastric cancer, postoperative complications, prognosis,  
25 overall survival

## 1           **Introduction**

2           Gastric cancer (GC) is the fifth most common type of cancer and third leading cause of death worldwide  
3 [1, 2]. Surgical resection or gastrectomy is the most important treatment for GC, but the postoperative  
4 complications (incidence rates of 12.8–14.0% [3-5]) negatively affects the patients' quality of life (QOL),  
5 subsequent treatment(s), and long-term survival [6, 7]. Several studies have confirmed the association of  
6 postoperative complications after gastrectomy for GC and poor oncological prognosis [8-10]. In 1994,  
7 laparoscopy-assisted distal end gastrectomy for early GC was introduced [11]; with advances in equipments  
8 and surgical techniques, laparoscopic gastrectomy (LG) has gradually been considered more often. In  
9 comparison to open gastrectomy, LG is associated with features such as feasibility, decreased surgical  
10 trauma, and a faster recovery. Further, many studies showed non-inferiority of LG to open gastrectomy for  
11 GC [12-14]. The impact of postoperative complications after LG for patients with GC remains controversial.  
12 In particular, laparoscopic total gastrectomy (LTG) requires a high degree of skill for performing the  
13 gastrectomy with systematic lymphadenectomy and post-resection reconstructions; the procedures are  
14 difficult and complex even for the experienced laparoscopic surgeons [15,16]. Further, the rates of  
15 complications after LTG are also reportedly high (7.6–42.6%) [17-19], but information on the postoperative  
16 complications-related adverse events (such as non-cancer-related deaths) is lacking. This study aimed to  
17 investigate the relationship between postoperative complications and long-term survival in patients who  
18 underwent LTG for GC.

## 20           **Methods**

### 21           Patients

22           We retrospectively reviewed all the patients who underwent curative LTG for GC at seven institutions  
23 (Hokkaido University Hospital, Teine Keijinkai Hospital, Obihiro-Kosei General Hospital, Hokkaido  
24 Gastroenterology Hospital, Tonan Hospital, Kitami Red Cross Hospital, and Asahikawa City Hospital)  
25 between January 2004 and December 2018. All patients were diagnosed with GC using endoscopy,  
26 computed tomography (CT), or endoscopic ultrasound. The Japanese Classification of Gastric Carcinoma  
27 (JCGC) was used for tumor staging [20]. The primary indication for LTG was stage I GC based on the  
28 Japanese Society of Endoscopic Surgery (JSES) guidelines [21]; however, over time, we expanded the  
29 indication to include cases of advanced GC that could be curatively resected.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Data collection

Clinicopathological data, including age, sex, body mass index (BMI), American Society of Anesthesiologists physical status (ASA-PS), clinical stage, combined resection of other organs, lymph node dissection, and anastomosis method, were collected. Surgical outcomes, including operative time, estimated blood loss, postoperative complications, and length of postoperative hospital stay, were recorded. Patients were categorized either to a complication group (CG) or non-complication group (non-CG), depending on the presence of serious postoperative complications ( $\geq$ CD IIIa: Clavien-Dindo grade III or higher complications) [22, 23]. All patients provided informed consent, and the Hokkaido University Hospital Institutional Review Board approved the data collection and analysis (No. 016-0151). This study was performed in accordance with the principles of the Declaration of Helsinki.

Surgical procedure

Gastric procedure type (resection and reconstruction) was determined based on the experience and preference of a surgeon who was accredited through the Endoscopic Surgical Skill Qualification System of the JSES [21]. In cases where the operating surgeon lacked this qualification, a qualified surgeon supervised the surgery. The extent of lymph node dissection was determined based on the JGCA guidelines [20]. Patients who underwent D2 lymph node dissection with splenectomy and D2–No.10 lymph node dissection were included in D1+. Patients were divided into three groups based on the Clavien-Dindo postoperative complication classification grade [22, 23].

Postoperative follow-up

All patients were observed every 3 months after surgery. Hematological analysis (including the tumor marker analysis for carcinoembryonic antigen and carbohydrate antigen 19–9) was performed at each visit. Abdominal CT scans were performed every 6 months or when clinical recurrence was suspected. Gastrointestinal endoscopy was performed at 1, 3, and 5 years postoperatively. Based on this surveillance, data on the 5-year overall survival (OS; time from surgery to death for any reason or follow-up interruption) and disease-specific survival (DSS; time from surgery to death from GC, including operative mortality or

1 follow-up interruption), and disease-free survival (DFS; time from surgery to death from GC, the first  
2 recurrence of GC, or follow-up interruption) were collected.

#### 3 4 Statistical analysis

5 Pearson's chi-square test and Fisher's exact probability test were performed for categorical variables.  
6 Mann–Whitney U tests were used to compare the clinicopathological characteristics for unpaired continuous  
7 variables between the two groups. Survival curves were estimated using the Kaplan–Meier method, and  
8 statistical differences were examined using the Wilcoxon test. A Cox proportional hazard regression model  
9 was used to determine the independent prognostic factors related to survival. Statistical significance was set  
10 at  $p < 0.05$ . Statistical analysis was performed using the JMP® 15 software (SAS Institute Inc., Cary, NC,  
11 USA).

### 12 13 **Results**

#### 14 Clinical features and surgical outcomes of the study population

15 A total of 459 patients were screened; after applying the exclusion criteria (neoadjuvant therapy, cStage  
16 IV, resection of other organs, and a total number of harvested lymph nodes  $\leq 15$ ), 411 patients were finally  
17 included in the analysis. In this study, for accurate prognostic analysis, we included more than 16 lymph  
18 nodes dissected using the exclusion criteria [24]. CG and non-CG groups had 65 and 346 patients,  
19 respectively (Fig. 1). Table 1 shows the clinical characteristics and surgical outcomes of the patients. Among  
20 total patients, 284 (69.1%) and 127 (30.9%) were males and females, respectively, with a median age of 68  
21 years (range 25–88) and median BMI of 23.0 kg/m<sup>2</sup> (range 13.6–38.9). The ASA-PS was  $\geq$ II in 286 (69.6%)  
22 patients, clinical JCGC stage was  $\geq$ II in 187 (45.5%) patients, D2 lymphadenectomy was performed in 67  
23 (16.3%) patients, median operation time was 330 (range, 123–762) min, median operative blood loss was 50  
24 (range, 0–1940) mL, serious postoperative complications ( $\geq$ CD IIIa) occurred in 65 patients (15.8%), and  
25 median postoperative hospital stay was 13 (range, 6–210) days.

26 Table 2 shows the clinicopathological characteristics of the study patients. No significant differences  
27 were observed in the age, BMI, ASA-PS, and clinical JCGC stage between the two groups. Female patients  
28 had significantly ( $p = 0.018$ ) fewer complications than that of the male patients. Table 3 shows the surgical  
29 outcomes in patients of the two groups. The median operative time, blood loss, extent of lymph node

1 dissection, method of esophagojejunostomy, and number of resected lymph nodes were not significantly  
2 different between the two groups; however, the median postoperative hospital stay was significantly ( $p$   
3  $<0.001$ ) longer in CG (34 days [range 8–210]) than that of the non-CG (12 days [range 6–43]). Further, the  
4 mortality was not observed in both the groups in 30 days postoperatively. Among the postoperative  
5 complications, esophagojejunostomy (EJS)-related complications (leakage or stenosis) were the most  
6 common (38.5 %) (Table 4).

## 7 8 Prognosis

9 Table 5 shows the histological examination results of resected specimens; the pathological JCGC stage  
10 were similar ( $p = 0.729$ ) in both the groups. The median follow-up periods for patients of the CG and non-  
11 CG were 36.7 (2–109.6 months) and 32.8 (1–139.2) months, respectively. During the follow-up period,  
12 postoperative recurrence was observed in 11 (16.9%) and 49 (14.7%) patients of the CG and non-CG,  
13 respectively, with no significance ( $p = 0.569$ ). Further, the median days until recurrence was significantly ( $p$   
14  $= 0.017$ ) shorter in CG (223 [range 60–1480] days) than that of the non-CG (469 [range 72–2289] days). For  
15 all the patients, the 5-year OS rate was 75.9%; 66.4 and 76.8% in the CG and non-CG, respectively. The  
16 Kaplan–Meier analysis for the OS indicated a significant ( $p = 0.001$ ) difference between the two groups (Fig.  
17 2a). The 5-year DSS and DFS rates were 80.3 and 75.3, 70.1 and 70.9, and 76.2 and 80.9% for all the patients,  
18 CG, and non-CG, respectively. The Kaplan–Meier analysis for DSS and DFS indicated significant (DSS,  $p$   
19  $= 0.011$ ; DFS,  $p = 0.001$ ) differences between the two groups (Fig. 2b,c).

## 20 21 Prognostic factors for OS, DSS and RFS

22 Table 6 shows the multivariate analysis conducted to assess the risk factors for OS, DSS, and DFS. In  
23 the OS, depth of tumor invasion (pT) and serious postoperative complications ( $\geq$ CD IIIa) were identified as  
24 the independent prognostic factors (pT: hazard ratio [HR] 0.194, 95% confidence interval [CI] 0.094–0.397],  
25  $p < 0.001$ ;  $\geq$ CD IIIa: HR 2.143, 95% CI 1.165–3.944,  $p = 0.014$ ). In DSS, pT, lymph node metastasis (pN),  
26 and serious postoperative complications ( $\geq$ CD IIIa) were identified as the independent prognostic factors  
27 ( $\geq$ CD IIIa: HR 2.467, 95% CI 1.223–4.975,  $p = 0.011$ ; pT: HR 0.156, 95% CI 0.062–0.394,  $p < 0.001$ ; pN:  
28 HR 2.289, 95% CI 1.088–4.814,  $p = 0.029$ ). In DFS, age, sex, and pT were independent prognostic factors



1 (age: HR 1.959, 95% CI 1.001–3.832,  $p = 0.004$ ; sex: HR 2.033, 95% CI 1.193–3.463,  $p = 0.009$ ; pT: HR  
2 0.192, 95% CI 0.095–0.385,  $p < 0.001$ ).

#### 4 **Discussion**

5 This is the first multicenter retrospective study that compared the serious postoperative complications  
6 and long-term outcomes associated with LTG for GC; we found that serious complications after LTG had a  
7 significant negative impact on the GC prognosis.

8 Severe postoperative complications increase the treatment costs, prolong the hospital stay, and have a  
9 negative effect on patients' QOL. The association of postoperative complications with the long-term survival  
10 has been suggested for malignant tumors, such as breast, colorectal, and periampullary cancers [25–28].  
11 Higher local recurrence risk and worse long-term outcomes in patients with GC were also reported to be  
12 related to postoperative complications [29, 30]. Kubota et al. evaluated the prognostic significance of  
13 postoperative complications in patients with GC using the propensity score matching analysis and reported  
14 a significant and independent correlation between the infectious complications and decreased survival [29].  
15 Tokunaga et al. also reported that postoperative intra-abdominal infectious complications (IaICs) in patients  
16 with GC predict a poor OS [8]. Hence, the presence of postoperative complications, especially infectious  
17 complications, in GC is significantly correlated with the disease recurrence and poor survival, and may be  
18 due to following reasons: (1) the inflammatory response, prolonged fasting conditions, and weight loss due  
19 to severe postoperative complications may result in immunosuppression. The cell-mediated immune  
20 response, particularly the cytotoxic T lymphocytes and natural killer cells, is compromised by systemic  
21 inflammation and surgical stress, promoting the immune escape of micrometastatic carcinoma cells [31, 32],  
22 (2) a large number of activated leukocytes and cytotoxic mediators such as interleukin-1 (IL-1), IL-6, and  
23 tumor necrosis factor- $\alpha$  released from the inflammatory response due to infection-related postoperative  
24 complications could accelerate the proliferation and invasion ability of residual cancer cells, which promotes  
25 the development of tumor recurrence and metastasis [33, 34], and (3) chemotherapy cannot be adequately  
26 administered.

27 Evans et al. [35] reported that laparoscopic surgery had little impact on the human immune function  
28 and induced a slight inflammatory reaction in elderly patients, which could effectively reduce the occurrence  
29 of cardiopulmonary complications. With the advancement of laparoscopic technology and accumulation of

1 surgical experience, laparoscopic gastrectomy is attracting attention as an alternative surgical method for  
2 patients with GC, and the occurrence of trauma and postoperative complications is expected to decrease  
3 further in the future. Regarding the long-term oncological results in LTG for GC, the 2-year OS and DFS  
4 rates were comparable between LTG and open total gastrectomy in meta-analysis studies [36, 37]. These  
5 results demonstrated that the surgical method did not affect long-term survival rates. Further, Jia-Bin Wang  
6 et al. reported that laparoscopic gastrectomy for GC can improve the prognosis of patients with postoperative  
7 IaICs and is therefore recommended for patients at a high risk of IaICs [38]. At present, the prognostic  
8 benefit of reduced surgical invasiveness with laparoscopy is controversial. In the present study also, we  
9 observed significantly worse 5-year OS, DSS, and DFS in patients with complications after LTG for GC.  
10 Furthermore, previous studies have also reported that weight loss associated with gastrectomy for GC  
11 decreased the nutritional status, postoperative QOL, and compliance of S-1 adjuvant chemotherapy, and  
12 could have led to the poor survival [39, 40]. Indeed, body weight loss at 1 year after surgery was reported to  
13 be approximately 10 and 15% following distal and total gastrectomy, respectively [41-43]. Weight loss after  
14 total gastrectomy may occur through various mechanisms, such as the hyper catabolism associated with  
15 inflammatory reactions due to surgical stress, reduced food intake owing to loss of reservoir function, and  
16 reduction in blood ghrelin level [44]. Furthermore, the postoperative complications related to EJS forces  
17 prolong fasting, resulting in poor nutritional status and QOL. The EJS stenosis increases the risk of aspiration  
18 pneumonia as well [45]. In the present study, the EJS-related complications were also the most common; it  
19 is necessary to establish simple EJS techniques that show less frequent postoperative complications.

20 Several recent studies have suggested that male gender is a risk factor for postoperative complications  
21 in bowel surgery.[46] Furthermore, male gender has also been associated with shorter overall survival and  
22 disease-free survival after anastomotic leakage, suggesting that the male risk factor deserves more attention  
23 [47, 48]. Our results in the present study showed that male gender was associated with more serious  
24 postoperative complications male ( $p = 0.018$ ). The gender difference may be explained by a combination of  
25 anatomical differences and the recently shown hormonal differences that influence the intestinal  
26 microcirculation [49]. Without a clear biological explanation for these findings and this finding should be  
27 interpreted with caution.

28 Randomized controlled studies have established that adjuvant chemotherapy following gastrectomy has  
29 survival advantages as compared to gastrectomy alone [50, 51]. Thus, adequate delivery and completion of

1 chemotherapy are necessary to obtain a survival benefit after curative gastrectomy for GC. Li et al. reported  
2 that the completion of multimodality therapy could extenuate the adverse influence of complications on the  
3 long-term survival of patients with locally advanced GC [52]. In the present study, no significant differences  
4 were observed in the number of patients receiving adjuvant chemotherapy between the two groups, but the  
5 median days until recurrence was significantly shorter in CG than that of non-CG); these findings indicate  
6 that postoperative complications could accelerate the proliferation and invasion ability of residual cancer  
7 cells. Moreover, the prognosis may have been worse in patients who were unable to complete multimodality  
8 therapy due to serious postoperative complications after LTG. The European Society for Medical Oncology  
9 (ESMO) suggests radical gastrectomy with free margins and an adequate lymphadenectomy, and if indicated  
10 along with perioperative neoadjuvant chemotherapy, as the standard of care in patients with advanced GC  
11 [53, 54]. Several recent studies demonstrated no difference in postoperative complication rates in gastric  
12 cancer patients who received neoadjuvant treatment compared with those undergoing operation first [55-57].  
13 In Japan, no evidence of perioperative neoadjuvant therapy is reported for GC. For patients with high risk of  
14 postoperative complications, neoadjuvant approach may be more beneficial to improve the chemotherapeutic  
15 agent compliance.

16 This study had several limitations. First, this was a retrospective, observational, and non-experimental  
17 study. Additionally, we included patients who underwent either laparo-assisted total gastrectomy (LATG)  
18 or totally laparoscopic total gastrectomy (TLTG); different results may have been obtained in an analysis  
19 with exclusion of patients who underwent LATG. Second, this study was conducted over a rather long period  
20 between 2004 and 2018, which may have resulted in historical biases in terms of the treatment strategies and  
21 perioperative management, affecting the short-term and prognostic outcomes after LTG. The detailed  
22 chemotherapy regimens administered after relapse and their impact were not known. Third, the surgical  
23 procedures and indication for GC were subjectively determined based on the experience of each surgeon.  
24 Fourth, shorter median follow-up time and underestimation of the survival differences between the two  
25 groups were possible. A well-designed randomized control trial is required to validate our findings.

26

## 27 **Conclusions**

1 Occurrence of serious postoperative complications after LTG showed a negative impact on the OS of  
2 the patients with GC. Strategies that decrease the complications after LTG are required for contributing  
3 towards better prognosis of patients with GC after LTG.

#### 5 **References**

6 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics,  
7 2012. *CA Cancer J Clin* 65(2):87–108. <https://doi.org/10.3322/caac.21262>. Epub 2015 Feb 4. PMID:  
8 25651787

9 2. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F (2021) Cancer  
10 statistics for the year 2020: an overview. *Int J Cancer*. <https://doi.org/10.1002/ijc.33588>. Epub ahead of print.  
11 PMID: 33818764

12 3. Yasunaga H, Horiguchi H, Kuwabara K, Matsuda S, Fushimi K, Hashimoto H, Ayanian JZ (2013)  
13 Outcomes after laparoscopic or open distal gastrectomy for early-stage gastric cancer: a propensity-matched  
14 analysis. *Ann Surg* 257(4):640–646. <https://doi.org/10.1097/SLA.0b013e31826fd541>, PMID: 23023204

15 4. Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, Ryu SW, Cho GS, Song KY, Ryu SY  
16 (2014) Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-  
17 matched Korean multicenter study. *J Clin Oncol* 32(7):627–633. <https://doi.org/10.1200/JCO.2013.48.8551>.  
18 Epub 2014 Jan 27. PMID: 24470012

19 5. Yu J, Hu J, Huang C, Ying M, Peng X, Wei H, Jiang Z, Du X, Liu Z, Liu H, Li G, Chinese  
20 Laparoscopic Gastrointestinal Surgery Study (CLASS) Group (2013) The impact of age and comorbidity on  
21 postoperative complications in patients with advanced gastric cancer after laparoscopic D2 gastrectomy:  
22 results from the Chinese laparoscopic gastrointestinal surgery study (CLASS) group. *Eur J Surg Oncol*  
23 39(10):1144–1149. <https://doi.org/10.1016/j.ejso.2013.06.021>. Epub 2013 Jul 10. PMID: 23850088

24 6. Fearon KC, Jenkins JT, Carli F, Lassen K (2013) Patient optimization for gastrointestinal cancer  
25 surgery. *Br J Surg* 100(1):15–27. <https://doi.org/10.1002/bjs.8988>. Epub 2012 Nov 20. PMID: 23165327

26 7. Yuan P, Wu Z, Li Z, Bu Z, Wu A, Wu X, Zhang L, Shi J, Ji J (2019) Impact of postoperative major  
27 complications on long-term survival after radical resection of gastric cancer. *BMC Cancer* 19(1):833.  
28 <https://doi.org/10.1186/s12885-019-6024-3>, PMID: 31443699, PMCID: PMC6708212

- 1        8. Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M (2013) Poor survival rate in  
2 patients with postoperative intra-abdominal infectious complications following curative gastrectomy for  
3 gastric cancer. *Ann Surg Oncol* 20(5):1575–1583. <https://doi.org/10.1245/s10434-012-2720-9>. Epub 2012  
4 Oct 18. PMID: 23076557
- 5        9. Kiuchi J, Komatsu S, Ichikawa D, Kosuga T, Okamoto K, Konishi H, Shiozaki A, Fujiwara H,  
6 Yasuda T, Otsuji E (2016) Putative risk factors for postoperative pneumonia which affects poor prognosis  
7 in patients with gastric cancer. *Int J Clin Oncol* 21(5):920–926. <https://doi.org/10.1007/s10147-016-0987-8>.  
8 Epub 2016 May 12. PMID: 27173949
- 9        10. Shimada H, Fukagawa T, Haga Y, Oba K (2017) Does postoperative morbidity worsen the  
10 oncological outcome after radical surgery for gastrointestinal cancers? A systematic review of the literature.  
11 *Ann Gastroenterol Surg* 1(1):11–23. <https://doi.org/10.1002/ags3.12002>, PMID: 29863169, PMCID:  
12 PMC5881350
- 13        11. Kitano S, Iso Y, Moriyama M, Sugimachi K (1994) Laparoscopy-assisted Billroth I gastrectomy.  
14 *Surg Laparosc Endosc* 4(2):146–148. Erratum in: *Surg Laparosc Endosc* (2013) 23(5):480. PMID: 8180768
- 15        12. Huscher CG, Mingoli A, Sgarzini G, Sansonetti A, Di Paola M, Recher A, Ponzano C (2005)  
16 Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized  
17 prospective trial. *Ann Surg* 241(2):232–237. <https://doi.org/10.1097/01.sla.0000151892.35922.f2>, PMID:  
18 15650632, PMCID: PMC1356907
- 19        13. Lee SW, Nomura E, Bouras G, Tokuhara T, Tsunemi S, Tanigawa N (2010) Long-term oncologic  
20 outcomes from laparoscopic gastrectomy for gastric cancer: a single-center experience of 601 consecutive  
21 resections. *J Am Coll Surg* 211(1):33–40. <https://doi.org/10.1016/j.jamcollsurg.2010.03.018>. Epub 2010  
22 May 26. PMID: 20610246
- 23        14. Liu D, Liang L, Liu L, Zhu Z, Liu S, Hu L, He Y, Fang Y, Wan X (2020) Short-term outcomes and  
24 prognosis of laparoscopy-assisted total gastrectomy in elderly patients with stomach cancer. *Surg Endosc*  
25 34(12):5428–5438. <https://doi.org/10.1007/s00464-019-07338-0>. Epub 2020 Jan 28. PMID: 31993813
- 26        15. Ebihara Y, Okushiba S, Kawarada Y, Kitashiro S, Katoh H (2013) Outcome of functional end-to-  
27 end esophagojejunostomy in totally laparoscopic total gastrectomy. *Langenbecks Arch Surg* 398(3):475–  
28 479. <https://doi.org/10.1007/s00423-013-1051-z>. Epub 2013 Jan 25. PMID: 23354359, PMCID:  
29 PMC3597276

- 1           16. Kitagami H, Morimoto M, Nakamura K, Watanabe T, Kurashima Y, Nonoyama K, Watanabe K,  
2 Fujihata S, Yasuda A, Yamamoto M, Shimizu Y, Tanaka M (2016) Technique of Roux-en-Y reconstruction  
3 using overlap method after laparoscopic total gastrectomy for gastric cancer: 100 consecutively successful  
4 cases. *Surg Endosc* 30(9):4086–4091. <https://doi.org/10.1007/s00464-015-4724-6>. Epub 2015 Dec 23.  
5 PMID: 26701704
- 6           17. Okabe H, Tsunoda S, Tanaka E, Hisamori S, Kawada H, Sakai Y (2015) Is laparoscopic total  
7 gastrectomy a safe operation? A review of various anastomotic techniques and their outcomes. *Surg Today*  
8 45(5):549–558. <https://doi.org/10.1007/s00595-014-0901-9>. Epub 2014 May 3. PMID: 24792009
- 9           18. Liu F, Huang C, Xu Z, Su X, Zhao G, Ye J, Du X, Huang H, Hu J, Li G, Yu P, Li Y, Suo J, Zhao  
10 N, Zhang W, Li H, He H, Sun Y; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group.  
11 (2020). Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric  
12 Cancer: The CLASS02 Multicenter Randomized Clinical Trial. *JAMA Oncol*. Oct 1;6(10):1590-1597. doi:  
13 10.1001/jamaoncol.2020.3152. PMID: 32815991; PMCID: PMC7441466.)
- 14           19. Zheng C, Xu Y, Zhao G, Cai L, Li G, Xu Z, Yan S, Wu Z, Xue F, Sun Y, Xu D, Zhang W, Wan J,  
15 Yu P, Hu J, Su X, Ji J, Li Z, You J, Li Y, Fan L, Lin J, Lin J, Li P, Huang C. (2021) Outcomes of Laparoscopic  
16 Total Gastrectomy Combined With Spleen-Preserving Hilar Lymphadenectomy for Locally Advanced  
17 Proximal Gastric Cancer: A Nonrandomized Clinical Trial. *JAMA Netw Open*. Dec 1;4(12):e2139992. doi:  
18 10.1001/jamanetworkopen.2021.39992. PMID: 34928353; PMCID: PMC8689389.
- 19
- 20           20. Japanese Gastric Cancer Association (2011) Japanese gastric cancer treatment guidelines 2010 (ver  
21 3). *Gastric Cancer* 14(2):113–123. <https://doi.org/10.1007/s10120-011-0042-4>
- 22           21. Japanese Society for Endoscopic Surgery (2014) Guidelines for the management of endoscopic  
23 surgery. Japanese Society for Endoscopic Surgery, Tokyo
- 24           22. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal  
25 with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 240(2):205–213.  
26 <https://doi.org/10.1097/01.sla.0000133083.54934.ae>, PMID: 15273542, PMCID: PMC1360123
- 27           23. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj  
28 J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The

- 1 Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg* 250(2):187–196.  
2 <https://doi.org/10.1097/SLA.0b013e3181b13ca2>, PMID: 19638912
- 3 24. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress  
4 DM, Byrd DR, Winchester DP (2017) The Eighth Edition AJCC Cancer Staging Manual: continuing to build  
5 a bridge from a population-based to a more “personalized” approach to cancer staging. *CA Cancer J Clin*,  
6 8th edn. 67(2):93–99. <https://doi.org/10.3322/caac.21388>. Epub 2017 Jan 17. PMID: 28094848
- 7 25. Murthy BL, Thomson CS, Dodwell D, Shenoy H, Mikeljevic JS, Forman D, Horgan K (2007)  
8 Postoperative wound complications and systemic recurrence in breast cancer. *Br J Cancer* 97(9):1211–1217.  
9 <https://doi.org/10.1038/sj.bjc.6604004>. Epub 2007 Oct 30. PMID: 17968426, PMCID: PMC2360477
- 10 26. Kressner U, Graf W, Mahteme H, Pählman L, Glimelius B (2002) Septic complications and  
11 prognosis after surgery for rectal cancer. *Dis Colon Rectum* 45(3):316–321. <https://doi.org/10.1007/s10350->  
12 [004-6174-4](https://doi.org/10.1007/s10350-004-6174-4), PMID: 12068187
- 13 27. Artinyan A, Orcutt ST, Anaya DA, Richardson P, Chen GJ, Berger DH (2015) Infectious  
14 postoperative complications decrease long-term survival in patients undergoing curative surgery for  
15 colorectal cancer: a study of 12,075 patients. *Ann Surg* 261(3):497–505.  
16 <https://doi.org/10.1097/SLA.0000000000000854>, PMID: 25185465
- 17 28. Cho JY, Han HS, Yoon YS, Hwang DW, Jung K, Kim YK (2013) Postoperative complications  
18 influence prognosis and recurrence patterns in periampullary cancer. *World J Surg* 37(9):2234–2241.  
19 <https://doi.org/10.1007/s00268-013-2106-6>, PMID: 23722466
- 20 29. Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, Aikou S, Watanabe R, Kosuga T,  
21 Yamaguchi T (2014) Prognostic significance of complications after curative surgery for gastric cancer. *Ann*  
22 *Surg Oncol* 21(3):891–898. <https://doi.org/10.1245/s10434-013-3384-9>. Epub 2013 Nov 20. PMID:  
23 24254205
- 24 30. Powell A, Coxon AH, Patel N, Chan D, Christian A, Lewis W (2018) Prognostic significance of  
25 post-operative morbidity severity score after potentially curative D2 gastrectomy for carcinoma. *J*  
26 *Gastrointest Surg* 22(9):1516–1527. <https://doi.org/10.1007/s11605-018-3787-9>. Epub 2018 May 15. PMID:  
27 29766446, PMCID: PMC6132392
- 28 31. Lerut T, Moons J, Coosemans W, Van Raemdonck D, De Leyn P, Decaluwé H, Decker G, Naftoux  
29 P (2009) Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and

1 gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of  
2 complications using the modified Clavien classification. *Ann Surg* 250(5):798–807.  
3 <https://doi.org/10.1097/SLA.0b013e3181bdd5a8>, PMID: 19809297

4 32. Roxburgh CS, Horgan PG, McMillan DC (2013) The perioperative immune/inflammatory insult in  
5 cancer surgery: time for intervention? *Oncoimmunology* 2(12):e27324. <https://doi.org/10.4161/onci.27324>.  
6 Epub 2013 Dec 9. PMID: 24498571, PMCID: PMC3909539

7 33. Saito T, Kurokawa Y, Miyazaki Y, Makino T, Takahashi T, Yamasaki M, Nakajima K, Takiguchi  
8 S, Mori M, Doki Y (2015) Which is a more reliable indicator of survival after gastric cancer surgery:  
9 postoperative complication occurrence or C-reactive protein elevation? *J Surg Oncol* 112(8):894–899.  
10 <https://doi.org/10.1002/jso.24067>. Epub 2015 Oct 13. PMID: 26458724

11 34. Okamura A, Takeuchi H, Matsuda S, Ogura M, Miyasho T, Nakamura R, Takahashi T, Wada N,  
12 Kawakubo H, Saikawa Y, Kitagawa Y (2015) Factors affecting cytokine change after esophagectomy for  
13 esophageal cancer. *Ann Surg Oncol* 22(9):3130–3135. <https://doi.org/10.1245/s10434-014-4348-4>. Epub  
14 2015 Jan 9. PMID: 25572684

15 35. Evans C, Galustian C, Kumar D, Hagger R, Melville DM, Bodman-Smith M, Jourdan I, Gudgeon  
16 AM, Dalglish AG (2009) Impact of surgery on immunologic function: comparison between minimally  
17 invasive techniques and conventional laparotomy for surgical resection of colorectal tumors. *Am J Surg*  
18 197(2):238–245. <https://doi.org/10.1016/j.amjsurg.2008.01.021>. Epub 2008 Jul 17. PMID: 18639228

19 36. Chen XZ, Wen L, Rui YY, Liu CX, Zhao QC, Zhou ZG, Hu JK (2015) Long-term survival outcomes  
20 of laparoscopic versus open gastrectomy for gastric cancer: a systematic review and meta-analysis. *Med*  
21 (Baltim) 94(4):e454. <https://doi.org/10.1097/MD.0000000000000454>, PMID: 25634185, PMCID:  
22 PMC4602964

23 37. Shen H, Shan C, Liu S, Qiu M (2013) Laparoscopy-assisted versus open total gastrectomy for  
24 gastric cancer: a meta-analysis. *J Laparoendosc Adv Surg Tech A* 23(10):832–840.  
25 <https://doi.org/10.1089/lap.2013.0152>. Epub 2013 Aug 27. PMID: 23980591

26 38. Wang JB, Que SJ, Chen QY, Zhong Q, Liu ZY, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Huang ZN,  
27 Lin JL, Zheng HL, Zheng CH, Li P, Huang CM, Xie JW (2021) Prognostic analysis of patients with intra-  
28 abdominal infectious complications after laparoscopic-assisted and open radical gastrectomy for gastric



1 cancer - A propensity score-matching analysis. *Surg Oncol* 37:101583.  
2 <https://doi.org/10.1016/j.suronc.2021.101583>. Epub 2021 May 14. PMID: 34087739

3 39. Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Tsuchida K, Hasegawa S, Cho H, Yukawa  
4 N, Oshima T, Rino Y, Masuda M, Tsuburaya A (2013) Body weight loss after surgery is an independent risk  
5 factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. *Ann Surg Oncol* 20(6):2000–2006.  
6 <https://doi.org/10.1245/s10434-012-2776-6>. Epub 2012 Dec 16. PMID: 23242818

7 40. Aoyama T, Sato T, Maezawa Y, Kano K, Hayashi T, Yamada T, Yukawa N, Oshima T, Rino Y,  
8 Masuda M, Ogata T, Cho H, Yoshikawa T (2017) Postoperative weight loss leads to poor survival through  
9 poor S-1 efficacy in patients with stage II/III gastric cancer. *Int J Clin Oncol* 22(3):476–483.  
10 <https://doi.org/10.1007/s10147-017-1089-y>. Epub 2017 Feb 7. PMID: 28176023

11 41. Davis JL, Selby LV, Chou JF, Schattner M, Ilson DH, Capanu M, Brennan MF, Coit DG, Strong  
12 VE (2016) Patterns and predictors of weight loss after gastrectomy for cancer. *Ann Surg Oncol* 23(5):1639–  
13 1645. <https://doi.org/10.1245/s10434-015-5065-3>. Epub 2016 Jan 5. PMID: 26732274, PMCID:  
14 PMC4862874

15 42. Takiguchi S, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Hosoda  
16 H, Kangawa K, Mori M, Doki Y (2016) Impact of synthetic ghrelin administration for patients with severe  
17 body weight reduction more than 1 year after gastrectomy: a phase II clinical trial. *Surg Today* 46(3):379–  
18 385. <https://doi.org/10.1007/s00595-015-1187-2>. Epub 2015 May 29. PMID: 26019019

19 43. Kim JW, Jung SY, Cho JW, Kim BC, Chung KS, Yang DH (2014) Postoperative Body Mass Index  
20 Changes in Gastric Cancer Patients according to Reconstruction Type: effectiveness of Long Jejunum Bypass  
21 on Weight Loss in Obese Patients after Distal Gastrectomy. *Indian J Surg* 76(3):187–192.  
22 <https://doi.org/10.1007/s12262-012-0651-0>. Epub 2012 Jul 8. PMID: 25177114, PMCID: PMC4141068

23 44. Ryan AM, Healy LA, Power DG, Rowley SP, Reynolds JV (2007) Short-term nutritional  
24 implications of total gastrectomy for malignancy, and the impact of parenteral nutritional support. *Clin Nutr*  
25 26(6):718–727. <https://doi.org/10.1016/j.clnu.2007.08.013>. Epub 2007 Oct 18. PMID: 17949863

26 45. Chen G, Wang J, Chen K, Kang M, Zhang H, Jin X, Lin L, Chen J (2021) Relationship between  
27 postoperative complications and the prognosis of gastric carcinoma patients who underwent surgical  
28 resection: A systematic review and meta-analysis. *Cancer Control* 28:10732748211011955.  
29 <https://doi.org/10.1177/10732748211011955>, PMID: 34018400, PMCID: PMC8204457

- 1           46. Kang SC, Kim HI, Kim MG (2016) Low Serum Albumin Level, Male Sex, and Total Gastrectomy  
2 Are Risk Factors of Severe Postoperative Complications in Elderly Gastric Cancer Patients. *J Gastric Cancer*.  
3 Mar;16(1):43-50.
- 4           47. Bell SW, Walker KG, Rickard MJ, Sinclair G, Dent OF, Chapuis PH, Bokey EL (2003) Anastomotic  
5 leakage after curative anterior resection results in a higher prevalence of local recurrence. *Br J Surg*.  
6 Oct;90(10):1261-6. doi: 10.1002/bjs.4219. PMID: 14515297.
- 7           48. Walker KG, Bell SW, Rickard MJ, Mehanna D, Dent OF, Chapuis PH, Bokey EL (2004)  
8 Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal  
9 cancer. *Ann Surg*. Aug;240(2):255-9. doi: 10.1097/01.sla.0000133186.81222.08. PMID: 15273549;  
10 PMCID: PMC1356401.
- 11           49. Ba ZF, Yokoyama Y, Toth B, Rue LW 3rd, Bland KI, Chaudry IH (2004) Gender differences in  
12 small intestinal endothelial function: inhibitory role of androgens. *Am J Physiol Gastrointest Liver Physiol*.  
13 Mar;286(3):G452-7. doi: 10.1152/ajpgi.00357.2003. Epub 2003 Oct 16. PMID: 14563675.
- 14           50. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H,  
15 Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, ACTS-GC Group (2007)  
16 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med* 357(18):1810–  
17 1820. <https://doi.org/10.1056/NEJMoa072252>. Erratum in: *N Engl J Med* (2008) 358(18):1977, PMID:  
18 17978289
- 19           51. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W,  
20 Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ, CLASSIC trial investigators (2014) Adjuvant  
21 capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (Classic): 5-year follow-up of an open-  
22 label, randomised phase 3 trial. *Lancet Oncol* 15(12):1389–1396. [https://doi.org/10.1016/S1470-](https://doi.org/10.1016/S1470-2045(14)70473-5)  
23 [2045\(14\)70473-5](https://doi.org/10.1016/S1470-2045(14)70473-5). Epub 2014 Oct 15. PMID: 25439693
- 24           52. Li SS, Udelsman BV, Parikh A, Klempner SJ, Clark JW, Roeland EJ, Wo JY, Hong TS, Mullen JT  
25 (2020) Impact of postoperative complication and completion of multimodality therapy on survival in patients  
26 undergoing gastrectomy for advanced gastric cancer. *J Am Coll Surg* 230(6):912–924.  
27 <https://doi.org/10.1016/j.jamcollsurg.2019.12.038>. Epub 2020 Feb 6. PMID: 32035978

- 1           53. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, ESMO Guidelines  
2 Committee (2016) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-  
3 up. *Ann Oncol* 27(suppl 5)(suppl 5):v38–v49. <https://doi.org/10.1093/annonc/mdw350>, PMID: 27664260
- 4           54. Rausei S, Boni L, Rovera F, Dionigi G (2013) Locally advanced gastric cancer: a new definition  
5 to standardise. *J Clin Pathol* 66(2):164–165. <https://doi.org/10.1136/jclinpath-2012-201176>. Epub 2012 Dec  
6 8. PMID: 23223567
- 7           55. Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ, Matamoros A, Das P, Mansfield P  
8 (2016) Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and  
9 Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. *Ann Surg Oncol*.  
10 Jan;23(1):156-62. doi: 10.1245/s10434-015-4643-8. Epub 2015 Jun 10. PMID: 26059652.
- 11           56. Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT (2016) Adjuvant  
12 Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus  
13 a Surgery-First Approach. *J Gastrointest Surg*. Jan;20(1):172-9; discussion 179. doi: 10.1007/s11605-015-  
14 2954-5. Epub 2015 Sep 22. PMID: 26394879.
- 15           57. Sun Z, Nussbaum DP, Speicher PJ, Czito BG, Tyler DS, Blazer DG 3<sup>rd</sup> (2015) Neoadjuvant radiation  
16 therapy does not increase perioperative morbidity among patients undergoing gastrectomy for gastric cancer.  
17 *J Surg Oncol*. Jul;112(1):46-50. doi: 10.1002/jso.23957. Epub 2015 Jul 14. PMID: 26179329.

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

1        **Figure legends**

2        Fig. 1 Study enrolments

3        LTG, laparoscopic total gastrectomy; NAC, Neoadjuvant therapy; CD, Clavien-Dindo.

4        \*In this study, for accurate prognostic analysis, we included the number of lymph nodes dissected to  
5        >16 in the exclusion criteria.

6

7        Fig. 2 Prognosis of patients who underwent laparoscopic total gastrectomy for gastric cancer according  
8        to age

9        (a) Overall, (b) disease-specific, and (c) disease-free survival

Table 1. Clinical features and surgical outcomes of the study population

Variable	Overall (n=411)
Gender (M/F)	284/127
Age (year) (median, range)	68 (25-88)
BMI <sup>†</sup> (kg/m <sup>2</sup> ) (median, range)	23.0 (13.6-38.9)
ASA-PS* (≥II) (patients,%)	286 (69.6%)
Clinical JCGC stage** (≥II) (patients,%)	187 (45.5%)
Lymph node dissection (≥D2) (patients,%)	67 (16.3%)
Operation time (min) (median, range)	330 (123-762)
Blood loss (ml) (median, range)	50 (0-1940)
Postoperative complication (CD <sup>§</sup> , ≥IIIa) (patients,%)	65 (15.8%)
Postoperative hospital stays (days) (median, range)	13 (6-210)

†Body mass index, \*The American Society of Anesthesiologist's physical status,

\*\*According to the Japanese classification of gastric carcinoma: 3rd English edition,

§ClavienDindo, classification

Table 2. Patient's characteristics of two groups

	Overall (n=411)		p value
	CG (n=65)	non-CG (n=346)	
Age (year) (median, range)	70 (25-85)	67 (33-88)	0.264
Sex (%)			0.018
Male	53 (81.5)	231 (66.8)	
Female	12 (18.5)	115 (33.2)	
BMI <sup>†</sup> (kg/m <sup>2</sup> ), median (range)	23.0 (14.0-30.9)	22.9 (13.6-38.9)	0.992
ASA-PS* (%)			0.755
1-2	61 (93.9)	328 (94.8)	
3-4	4 (6.1)	18 (5.2)	
Clinical JCGC stage** (%)			0.729
I	35 (53.9)	189 (54.6)	
II	18 (27.7)	82 (23.7)	
III	12 (18.4)	75 (21.7)	

†BMI, Body mass index, \*The American Society of Anaesthesiologist's physical status,

\*\*According to the Japanese classification of gastric carcinoma: 3rd English edition.

Table 3. Surgical outcomes of two groups

	Overall (n=411)		p value
	CG (n=65)	non-CG (n=346)	
Operative time (min), median (range)	350 (123-648)	330 (171-762)	0.172
Blood loss (mL), median (range)	63.5 (0-1940)	50.0 (0-1160)	0.128
Extent of lymph node dissection			0.607
D1/D1+ (%)	53 (81.5)	291 (84.1)	
D2 (%)	12 (18.5)	55 (15.9)	
Esophagojejunostomy (Linear stapler/Circular stapler/Unknown)	36/29/0	218/124/4	0.302
Number of harvested lymph nodes, median (range)	41 (17-105)	41 (16-114)	0.208
Postoperative hospital stay (day), median (range)	34 (8-210)	12 (6-43)	<0.001
Mortality (within 30 days)	0	0	

Table 4. Postoperative complications in the complication group (CG)

Postoperative complications	CG (n=65)
EJS <sup>†</sup> leakage	13
EJS <sup>†</sup> stenosis	12
Duodenal stump leakage	10
Pancreatic fistula	5
Pneumonia	1
Abdominal abscess	7
Postoperative bleeding	6
Ileus	6
Others	5

<sup>†</sup>Esophagojejunostomy



Table 5. Pathological results and recurrence site of two groups


	Overall (n=411)		p value
	CG (n=65)	non-CG (n=346)	
Pathological JCGC stage* (%)			0.729
I	35 (53.9)	189 (54.6)	
II	18 (27.7)	82 (23.7)	
III	12 (18.4)	75 (21.7)	
Adjuvant chemotherapy	15 (23.1)	100 (28.9)	0.337
Recurrence (Y/N)	11/54	49/296	0.569
Recurrence site			
LN (Regional/Para Ao/Distant)	0/1/0	4/5/2	
Peritoneum dissemination	4	18	
Liver metastasis	5	12	
Lung metastasis	0	5	
Brain metastasis	0	1	
Bone metastasis	1	1	
Port site recurrence	0	1	
Days until recurrence (day), median (range)	223 (60-1480)	469 (72-2289)	0.017


\*According to the Japanese classification of gastric carcinoma: 3rd English edition.

Table 6. Multivariate Cox regression analyses for overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS)


	OS		DSS		DFS	
	HR (95%CI)	p value	HR (95%CI)	p value	HR (95%CI)	p value
Age (year) ( $\geq 80$ / $<80$ )					1.959 (1.001-3.832)	0.004
Sex (M / F)					2.033 (1.193-3.463)	0.009
Postoperative complication (CD <sup>§</sup> $\geq$ IIIa / CD $<$ IIIa)	2.143 (1.165-3.944)	0.014	2.467 (1.223-4.975)	0.011		
pT (1 / 2,3)	0.194 (0.094-0.397)	<0.0001	0.156 (0.062-0.394)	<0.0001	0.192 (0.095-0.385)	<0.0001
pN (Y / N)			2.289 (1.088-4.814)	0.029		

<sup>§</sup>Clavien-Dindo, classification






		No. at risk					
			12	24	36	48	60
—	< CD IIIa	346	272	213	159	112	81
—	≥ CD IIIa	65	42	38	32	22	14



		No. at risk					
			12	24	36	48	60
—	< CD IIIa	346	249	190	137	102	76
—	≥ CD IIIa	65	40	35	31	21	14



		No. at risk					
			12	24	36	48	60
—	< CD IIIa	346	272	213	159	112	81
—	≥ CD IIIa	65	42	38	32	22	14